Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001267557 | SCV001445738 | likely pathogenic | Inborn genetic diseases | 2020-09-30 | criteria provided, single submitter | clinical testing | The c.676_678delGAT (p.D226del) alteration, located in exon 11 (coding exon 9) of the HNRNPK gene, results from an in-frame 3 nucleotide deletion at positions 676 to 678. This results in the deletion of an aspartic acid (D) residue at codon 226. Based on data from the Genome Aggregation Database (gnomAD), the HNRNPK c.676_678delGAT alteration was not observed, with coverage at this position. This alteration has been identified as a de novo event in multiple individuals (Ambry internal data). The p.D226 amino acid is conserved in available vertebrate species. The p.D226del alteration is predicted to be deleterious with a score of -12.372 by PROVEAN in silico analysis. Based on the available evidence, this alteration is classified as likely pathogenic. |